Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate-Reference-Cited by-同舟云学术

Search of official nationwide database in Japan for adverse events associated with disease-modifying antirheumatic drug therapies: focus on therapies in combination with methotrexate

Published:2021-11-11 Issue: Volume: Page:
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Inokuma Shigeko¹

Affiliation:

1. Chiba Central Medical Center; National Center for Global Health and Medicine, Kohnodai Hospital, Chiba, Japan

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2006180

Reference26 articles.

1. 1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960–977.

2. 2. Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2018 May 24(E-pub ahead of print).

3. 3. Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, et al. Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2016;26:491–498.

4. 4. Yamanaka H, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan. Mod Rheumatol 2015;25:495–502.

5. 5. Saeki Y, Matsui T, Saisho K, Tohma S. Current treatments of rheumatoid arthritis: from the ‘NinJa’ registry. Expert Rev Clin Immunol. 2012;8:455–465.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of methotrexate‐related lymphoproliferative disorder resolved with discontinuation of the drug: A literature review for clinical characteristics in 105 Japanese cases;Journal of Cutaneous Immunology and Allergy;2023-09-11

2. Outcomes and risk factors for mortality in Pneumocystis pneumonia patients with rheumatoid arthritis: A multicentre retrospective cohort study;Modern Rheumatology;2022-08-03

3. AB0382 COMPARISON OF ADVERSE EVENTS (AEs) RELATED TO MAJOR ANTI-RHEUMATIC DRUGS, REPORTED TO THE OFFICIAL JAPANESE ADVERSE DRUG EVENT REPORT DATABASE (JADER);Annals of the Rheumatic Diseases;2022-05-23

4. Impact of Janus kinase inhibitors on antibody response to 13-valent pneumococcal conjugate vaccine in patients with rheumatoid arthritis;Modern Rheumatology;2022-03-26